Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Nature · 2021
    RZRoberta ZappasodiISInna Sergeevna SerganovaJKJason KoutcherJDJedd D WolchokTMTaha Merghoub
    PMID: 33588426PMCID: PMC8057670DOIFirst author366 citations
  2. 2
    Oncotarget · 2023
    RZRoberta Zappasodi
    PMID: 37335294PMCID: PMC10278658DOISenior author21 citations
  3. 3
    Methods in enzymology · 2019
    RZRoberta ZappasodiSBSadna BudhuTMTaha Merghoub
    PMID: 31948562PMCID: PMC7362725DOIFirst author18 citations

Publications

74 publications

Funding

23 grantsView NIH portfolio on RePORTER ↗

Active

16 grants
  • Co-I
    The role of MGA in the pathogenesis of Richter Transformation
    National Cancer Institute · 2026–2031
    R37CA304192-01A1
  • Co-I
    SPORE: Adressing Health Disparities in Lymphoma
    National Cancer Institute · 2025–2030 · via MD Anderson Cancer Center· 3 renewals
    U54CA302435-01
  • Co-I
    Targeting the melanoma metabolic microenvironment to boost T-cell therapy
    Melanoma Research Alliance · 2026–2029
    1584423
  • PI
    Improving immunotherapy by modulating PD-1hiFoxp3-CD4+ T cells in melanoma
    Melanoma Research Foundation · 2026–2028
    MRF 261760-01
  • PI
    Effects of tumor energetics on anti-tumor immunity through vasculature remodeling
    The G. Harold and Leila Y. Mathers Foundation · 2025–2028
    GHL 251782-02
  • PI
    Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
    National Cancer Institute · 2023–2028· 2 renewals
    R01CA282889-04
  • Co-I
    PICI Grant and Main Collaboration Agreement with Multiple Subprojects
    Parker Institute for Cancer Immunotherapy · 2024–2028
    PICI 235170-03
  • MPI
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23 Project 1
  • Co-I
    Elucidating the Role of the Tumor Suppressor KEAP1 in Antitumor Immunity
    National Cancer Institute · 2025–2027
    R01CA296867-01A1
  • PI
    Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunity
    Cancer Research Institute, Inc. · 2025–2027
    CRI13928
  • MPI
    Research Collaboration Agreement- Treeline Biosciences, Inc.
    Treeline Biosciences INC · 2024–2027BioPharma Alliance
    BP 240939-02
  • PI
    Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic Targeting
    Starr Cancer Consortium · 2024–2026
    I17-0132
  • MPI
    Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
    National Cancer Institute · 2024–2026
    P01CA272295-02
  • PI
    CD36 in breast cancer
    Pilatus Biosciences Inc · 2025–2026Contract
    SRA 234221-01
  • Co-I
    COG Hodgkin Lymphoma (Defining Biomarkers of Response to Immunotherapy in Pediatric Hodgkin Lymphoma - The Jeffrey Pride Foundation Integrated Correlative Biology Awards)
    Jeffrey Pride Foundation INC · 2024–2026 · via Children's Oncology Group
    NY018_2024_01_ROTH
  • PI
    Investigating the tumor metabolism-hypoxia-vasculature axis in the response of TNBC to immunotherapy
    Fondazione AIRC per la Ricerca sul Cancro · 2024–2026
    No publications yet
    FAIRC 232007-02
Completed grants (7)
  • PI
    Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy.
    Leukemia & Lymphoma Society · 2021–2025
    LLS 6643-22
  • MPI
    Targeting immune escape in Cluster 5 DLBCL
    AstraZeneca Pharmaceuticals LP · 2021–2025Contract
    SRA 215352-02
  • PI
    Tumor-metabolism-driven therapies to overcome TNBC immune resistance
    Breast Cancer Alliance Inc. · 2023–2025
    BCA 225494-02
  • PI
    SRA with BMS
    Bristol-Myers Squibb · 2021–2024Contract
    SRA 215059-02
  • KP
    Hypoxic incubator for physiological cell culture research
    Office of the Director, NIH · 2022–2023
    S10OD032317-01
  • PI
    Dissecting the role of CD4+ TFH-like cells as a therapeutic target and biomarker of immunotherapy activity
    Parker Institute for Cancer Immunotherapy · 2020–2022Contract
    SRA 203365-02
  • MPI
    Immune Crosstalk In Non-Hodgkin B-Cell Lymphomas As A Therapeutic Vulnerability
    National Cancer Institute · 2020–2022 · via Memorial Sloan Kettering Cancer Center
    P50CA192937-05

Clinical research

1 study

Active

1 study
  • PI
    AI Digital Pathology Tools to Improve Lymphoma Diagnosis and Classification
    MD Anderson Cancer Center · OPEN TO ACCRUAL (as of 2026)

News mentions

1 mentionView all WCM news ↗

Mentoring

7 menteesAll publications with mentees →

External relationships

Other

iTeos Therapeutics